DARE חוב כולל להון Daré Bioscience, Inc.

Dare Bioscience, Inc. (DARE) research centers are developing unique treatment methods in niches with a deficit of therapies. Current revenue is based on royalties from sales of the first approved gel, while future growth is expected from clinical trial data. The biotech company focuses on innovative contraception for women worldwide. This chart of the share price on GURU.Markets shows that the debt-to-equity ratio is 0.00.

Effective R&D pipeline management and big pharma partnerships under Sabrina Johnson's leadership allow Dare Bioscience, Inc. (DARE) to optimize its financial leverage. By analyzing the current total debt-to-equity ratio, an investor assesses the proportion of borrowed funds to net assets, where an increasing value signals a heavier credit burden, while an excessive decrease indicates an underutilization of debt financing potential for scaling the business.